Patient demographics and serum vitamin D levels
| Patient . | Sex . | Age . | Weight (kg) . | Diagnostic group . | Autologous/allogeneic transplant . | Vitamin D Stoss dose before HSCT? . | Additional enteral cholecalciferol supplementation after STOSS at enrollment? . | Enrollment timing after transplantation . | Median serum vitamin D (ng/mL) in the year before starting OTF strips . | Baseline serum vitamin D (ng/mL) . | Median serum vitamin D on study (ng/mL) . | End-of-study serum vitamin D (ng/mL) . | Average dose on study . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 18 y | 59.6 | Malignancy | Allogeneic | Y | Y: 50 000 IU per wk | Day +225 | 26.3 | 30.1 | 52.6 | 69.1 | 2 OTFs per wk |
| 2 | F | 5 y | 16.3 | Benign hematology | Allogeneic | Y | Y: 50 000 IU per wk | Day +112 | 27.9 | 24.6 | 53.2 | 77.9 | 1 OTF per wk |
| 3 | F | 20 mo | 13.0 | Malignancy | Autologous | Y | Y: 5000 IU per wk | Day +31 | 31.7 | 26.1 | 53.4 | 54.4 | 1 OTF every other wk |
| 4 | M | 4 y | 19.5 | Immune disorder | Allogeneic | Y | Y: 50 000 IU per wk | Day +34 | 43.0 | 25.0 | 53.0 | 67.0 | 1 OTF per wk |
| 5 | F | 9 y | 20.5 | Immune disorder | Allogeneic | Y | N | Day +26 | 41.0 | 34.6 | 54.1 | 39.4 | 1 OTF every other wk |
| 6 | M | 17 y | 65.1 | Malignancy | Allogeneic | Y | Y: 50 000 IU per wk | Day +52 | 29.8 | 29.7 | 52.2 | 82.5 | 2 OTFs per wk |
| 7 | M | 7 y | 21.4 | Malignancy | Allogeneic | Y | Y: 50 000 IU per wk | Day +21 | 50.5 | 35.8 | 52.4 | 100.8 | 1 OTF per wk |
| 8 | M | 8 y | 25.6 | Immune disorder | Allogeneic | Y | Y: 50 000 IU per wk | Day +328 | 33.8 | 34.6 | 52.2 | 41.6 | 1 OTF per wk |
| 9 | F | 28 y | 47.0 | Marrow failure | Allogeneic | Y | N | Day +64 | 28.9 | 29.0 | 53.0 | 51.4 | 1 OTF per wk |
| 10 | F | 16 mo | 11.1 | Marrow failure | Allogeneic | Y | N | Day +156 | 33.2 | 30.5 | 53.0 | 60.4 | 1 OTF every other wk |
| 11 | F | 9 y | 24.7 | Malignancy | Allogeneic | Y | Y: 50 000 IU per wk | Day +428 | 31.0 | 27.9 | 53.0 | 42.3 | 1 OTF every other wk |
| 12 | M | 4 y | 17.3 | Marrow failure | Allogeneic | Y | N | Day +75 | 37.5 | 25.1 | 52.2 | 48.5 | 1 OTF every other wk |
| 13 | M | 19 y | 88.9 | Malignancy | Allogeneic | Y | N | Day +24 | 20.6 | 28.0 | 52.1 | 36.7 | 3 OTFs per wk |
| 14 | M | 18 y | 36.5 | Malignancy | Allogeneic | Y | Y: 50 000 IU per wk | Day +296 | 34.5 | 26.5 | 53.5 | 64.0 | 1 OTF per wk |
| 15 | M | 9 y | 22.7 | Benign hematology | Allogeneic | Y | N | Day +75 | 29.4 | 29.4 | 53.4 | 45.1 | 1 OTF per wk |
| 16 | M | 22 y | 77.9 | Immune disorder | Allogeneic | Y | Y: 50 000 IU per wk | Day +19 | 29.8 | 23.9 | 53.7 | 55.5 | 1 OTF per wk |
| 17 | M | 13 mo | 8.5 | Immune disorder | Allogeneic | Y | N | Day +50 | 36.6 | 33.9 | 53.5 | 42.5 | 1 OTF every 3 wks |
| 18 | M | 2 y | 8.7 | Marrow failure | Allogeneic | Y | Y: 50 000 IU per wk | Day +71 | 33.2 | 33.2 | 52.2 | 62.3 | 1 OTF every 3 wks |
| 19 | M | 8 y | 20.5 | Benign hematology | Allogeneic | Y | N | Day +96 | 35.5 | 35.0 | 48.2 | 70.7 | 1 OTF every other wk |
| 20 | M | 4 y | 19.5 | Malignancy | Allogeneic | Y | Y: 10 000 IU per wk | Day +52 | 40.5 | 24.5 | 40.8 | 86.4 | 1 OTF per wk |
| Patient . | Sex . | Age . | Weight (kg) . | Diagnostic group . | Autologous/allogeneic transplant . | Vitamin D Stoss dose before HSCT? . | Additional enteral cholecalciferol supplementation after STOSS at enrollment? . | Enrollment timing after transplantation . | Median serum vitamin D (ng/mL) in the year before starting OTF strips . | Baseline serum vitamin D (ng/mL) . | Median serum vitamin D on study (ng/mL) . | End-of-study serum vitamin D (ng/mL) . | Average dose on study . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 18 y | 59.6 | Malignancy | Allogeneic | Y | Y: 50 000 IU per wk | Day +225 | 26.3 | 30.1 | 52.6 | 69.1 | 2 OTFs per wk |
| 2 | F | 5 y | 16.3 | Benign hematology | Allogeneic | Y | Y: 50 000 IU per wk | Day +112 | 27.9 | 24.6 | 53.2 | 77.9 | 1 OTF per wk |
| 3 | F | 20 mo | 13.0 | Malignancy | Autologous | Y | Y: 5000 IU per wk | Day +31 | 31.7 | 26.1 | 53.4 | 54.4 | 1 OTF every other wk |
| 4 | M | 4 y | 19.5 | Immune disorder | Allogeneic | Y | Y: 50 000 IU per wk | Day +34 | 43.0 | 25.0 | 53.0 | 67.0 | 1 OTF per wk |
| 5 | F | 9 y | 20.5 | Immune disorder | Allogeneic | Y | N | Day +26 | 41.0 | 34.6 | 54.1 | 39.4 | 1 OTF every other wk |
| 6 | M | 17 y | 65.1 | Malignancy | Allogeneic | Y | Y: 50 000 IU per wk | Day +52 | 29.8 | 29.7 | 52.2 | 82.5 | 2 OTFs per wk |
| 7 | M | 7 y | 21.4 | Malignancy | Allogeneic | Y | Y: 50 000 IU per wk | Day +21 | 50.5 | 35.8 | 52.4 | 100.8 | 1 OTF per wk |
| 8 | M | 8 y | 25.6 | Immune disorder | Allogeneic | Y | Y: 50 000 IU per wk | Day +328 | 33.8 | 34.6 | 52.2 | 41.6 | 1 OTF per wk |
| 9 | F | 28 y | 47.0 | Marrow failure | Allogeneic | Y | N | Day +64 | 28.9 | 29.0 | 53.0 | 51.4 | 1 OTF per wk |
| 10 | F | 16 mo | 11.1 | Marrow failure | Allogeneic | Y | N | Day +156 | 33.2 | 30.5 | 53.0 | 60.4 | 1 OTF every other wk |
| 11 | F | 9 y | 24.7 | Malignancy | Allogeneic | Y | Y: 50 000 IU per wk | Day +428 | 31.0 | 27.9 | 53.0 | 42.3 | 1 OTF every other wk |
| 12 | M | 4 y | 17.3 | Marrow failure | Allogeneic | Y | N | Day +75 | 37.5 | 25.1 | 52.2 | 48.5 | 1 OTF every other wk |
| 13 | M | 19 y | 88.9 | Malignancy | Allogeneic | Y | N | Day +24 | 20.6 | 28.0 | 52.1 | 36.7 | 3 OTFs per wk |
| 14 | M | 18 y | 36.5 | Malignancy | Allogeneic | Y | Y: 50 000 IU per wk | Day +296 | 34.5 | 26.5 | 53.5 | 64.0 | 1 OTF per wk |
| 15 | M | 9 y | 22.7 | Benign hematology | Allogeneic | Y | N | Day +75 | 29.4 | 29.4 | 53.4 | 45.1 | 1 OTF per wk |
| 16 | M | 22 y | 77.9 | Immune disorder | Allogeneic | Y | Y: 50 000 IU per wk | Day +19 | 29.8 | 23.9 | 53.7 | 55.5 | 1 OTF per wk |
| 17 | M | 13 mo | 8.5 | Immune disorder | Allogeneic | Y | N | Day +50 | 36.6 | 33.9 | 53.5 | 42.5 | 1 OTF every 3 wks |
| 18 | M | 2 y | 8.7 | Marrow failure | Allogeneic | Y | Y: 50 000 IU per wk | Day +71 | 33.2 | 33.2 | 52.2 | 62.3 | 1 OTF every 3 wks |
| 19 | M | 8 y | 20.5 | Benign hematology | Allogeneic | Y | N | Day +96 | 35.5 | 35.0 | 48.2 | 70.7 | 1 OTF every other wk |
| 20 | M | 4 y | 19.5 | Malignancy | Allogeneic | Y | Y: 10 000 IU per wk | Day +52 | 40.5 | 24.5 | 40.8 | 86.4 | 1 OTF per wk |
F, female; M, male; N, no; Y, yes.